Research journal
What this dataset cannot tell you
A price database is only as useful as its account of its own limits. These are the questions this site cannot currently answer, why, and what would close each gap.
What a mid-ladder dose costs
10 of 27 rankable tirzepatide programs and 8 of 29 semaglutide programs do not publish a price at every dose. For those, what you pay in the middle of a titration is not publicly established, and we show the gap rather than estimating across it. Only the provider can close this one.
Who actually compounds the medication
29 of the 37 programs in this database do not name their compounding pharmacy. Where the pharmacy is unnamed, its licensing, inspection history and testing cannot be checked by anyone — not by us and not by you. This is the most consequential open question in the dataset, because it defeats every downstream quality check.
Where each program actually ships
28 programs describe availability in prose — variations of "most US states" or "confirm at intake" — rather than as a list. There are therefore no per-state pages on this site. Building them would mean establishing coverage state by state as original research, not transforming data we hold, and publishing a state page without that work would be inventing coverage.
Programs with no comparable price
11 program-medication records publish no maintenance-dose figure and are excluded from every ranking. They appear in the database with the reason stated. Ranking them on an advertised starting price would put the least informative number at the top of a cheapest list.
- Fifty 410 — tirzepatide: no maintenance-dose price published
- Henry Meds — tirzepatide: No injectable tirzepatide offered, and no month-to-month rate published for the oral product. An oral dissolving tablet is not comparable to an injection-maintenance basis.
- LumiMeds — tirzepatide: no maintenance-dose price published
- Sprout Health — tirzepatide: no maintenance-dose price published
- Sprout Health — semaglutide: no maintenance-dose price published
- Strut Health — tirzepatide: no maintenance-dose price published
- Strut Health — semaglutide: no maintenance-dose price published
- Synergy Rx — tirzepatide: no maintenance-dose price published
- Synergy Rx — semaglutide: no maintenance-dose price published
- Trimi — tirzepatide: no maintenance-dose price published
- Trimi — semaglutide: no maintenance-dose price published
Whether any of this works for you
This site measures price. It does not measure outcomes, tolerability, or the quality of any program's clinical care, and it has no mechanism that could. Trial evidence for GLP-1 weight loss comes from the FDA-approved products at labelled doses; it does not transfer to compounded preparations, whose manufacturing has not been reviewed pre-market. Those are questions for a licensed clinician.
Questions
Why are there no state-by-state pages?
Because no provider publishes machine-readable state coverage — they describe it as 'most US states' or 'confirm at intake'. Building state pages would require establishing coverage as original research, and publishing them without it would be inventing coverage.
Why are some programs missing from the rankings?
11 program-medication records publish no maintenance-dose price. They stay in the database with the reason stated but cannot enter a like-for-like ranking.
Does this site assess clinical quality?
No. It measures price and disclosure. It does not measure outcomes, tolerability or the quality of clinical care, and it has no mechanism that could.